Category - Developments

Developments

Dicerna gets FDA orphan drug designation for alpha-1 antitrypsin deficiency drug candidate

Dicerna Pharma (NASDAQ:DRNA) received FDA orphan drug designation for DCR-A1AT for the treatment of alpha-1 antitrypsin deficiency, a genetic disorder that can cause lung and liver disease. The company submitted a...

March 19, 2020

Developments

NantKwest doses first patient in Phase 2 Merkel cell carcinoma study

NantKwest (NASDAQ:NK) dosed the first patient in its Phase 2 trial for second- and third-line Merkel cell carcinoma (MCC). MCC is a rare and aggressive skin cancer that is fatal for the majority of patients who have...

March 19, 2020

Developments

Soligenix reports positive topline results from Phase 3 cutaneous T-cell lymphoma trial

Soligenix (NASDAQ:SNGX) reported positive topline results for its Phase 3 trial assessing SGX301 for the treatment of cutaneous T-cell lymphoma (CTCL). The study enrolled 169 patients who were randomized to receive...

March 19, 2020

Developments

Abeona treats first patient in Phase 3 VIITAL gene therapy trial

Abeona Therapeutics (NASDAQ:ABEO) treated the first patient in its Phase 3 clinical trial evaluating EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The trial, being conducted at Stanford...

March 19, 2020

Developments

Alpine Immune Sciences gets two FDA orphan drug designations for ALPN-101

Alpine Immune Sciences (NASDAQ:ALPN) received two FDA orphan drug designations for ALPN-101 for the prevention and treatment of acute graft-versus-host disease (GvHD). ALPN-101 is a selective dual T-cell co-stimulation...

March 19, 2020

Developments

Sigilon Therapeutics in $80.3-million series B financing

Closely-held Sigilon Therapeutics completed an $80.3-million Series B financing to advance its Shielded Living Therapeutics platform to the clinic. The funding will support the first-in-human clinical trial of Sigilon’s...

March 18, 2020

Developments

Hepion’s CRV431 shows potential to treat idiopathic pulmonary fibrosis

Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive findings from a translational research study assessing the effects of CRV431 on lung tissue obtained from a patient with idiopathic pulmonary fibrosis (IPF). In the...

March 12, 2020

Developments

Bee Vectoring kick starts U.S. west coast expansion

Bee Vectoring Technologies International (TSXV, CVE:BEE; OTCQB:BEVVF) closed three new grower deals with berry producers in Oregon and Washington states to use the company’s proprietary bee delivery system, VECTORITE...

March 11, 2020

Developments

Albireo Pharma completes patient enrollment in Phase 2 NASH/NAFLD study

Albireo Pharma (NASDAQ:ALBO) completed patient enrollment in its Phase 2 trial of elobixibat for the treatment of nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD). The trial enrolled 47...

March 10, 2020

Developments

Mackie Research: 2018 Farm Bill leads to misconceptions about what CBD products you can legally sell in U.S.

According to the FDA, the passage of the 2018 Farm Bill has led to the misperception that all products made from or containing hemp, including those made with cannabidiol (CBD), were now legal to sell in interstate...

March 10, 2020

Category - Developments

Dicerna gets FDA orphan drug designation for alpha-1 antitrypsin deficiency drug candidate

NantKwest doses first patient in Phase 2 Merkel cell carcinoma study

Soligenix reports positive topline results from Phase 3 cutaneous T-cell lymphoma trial

Abeona treats first patient in Phase 3 VIITAL gene therapy trial

Alpine Immune Sciences gets two FDA orphan drug designations for ALPN-101

Sigilon Therapeutics in $80.3-million series B financing

Hepion’s CRV431 shows potential to treat idiopathic pulmonary fibrosis

Bee Vectoring kick starts U.S. west coast expansion

Albireo Pharma completes patient enrollment in Phase 2 NASH/NAFLD study

Mackie Research: 2018 Farm Bill leads to misconceptions about what CBD products you can legally sell in U.S.

General

More